Clinical trial
Phase II Study of ONTAK in Previously Treated Patients With Low-grade…
NCT00051025 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00051025 |
|---|---|
| Title | Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL) |
| Official title | A Randomized, Multicenter, Phase II Evaluation of ONTAK (Denileukin Diftitox) in Patients With Previously Treated, Indolent, B-Cell, Non-Hodgkin's Lymphoma |
| Lead sponsor | Eisai Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma, Lymphoma, B-cell, Low-grade |
| Intervention type | Drug |
| Interventions | ONTAK |
| Enrollment | 9 |
| Start date | May 1, 2000 |
| Primary completion | Jan 1, 2001 |
| Completion | Sep 1, 2006 |
| First posted | Jan 3, 2003 |
| Last update posted | Jul 13, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: